03/01/2026
2026: A New Standard for Cancer Care 🧬
Towards the end of 2025, a landmark Phase III trial in The Lancet officially changed the conversation around Proton Beam Therapy (PBT). PBT is now confirmed as a new standard of care for head and neck cancers.
For the first time, this major study proves we can improve survival rates while simultaneously reducing life-altering side effects.
The Results:
✅ 10% increase in 5-year overall survival. ✅ 42% reduction in the hazard of death. ✅ Fewer complications: Better swallowing, less dry mouth, and reduced feeding tube dependence.
At Proton International London, our Chief Medical Officer (CMO) Dr. J.W. Snider served as a primary investigator for this global trial. We are proud to bring this world-leading, Level 1 evidence to our patients today.
In 2026, precision isn’t just an option—it’s the benchmark.
🔗 Read the full study breakdown via the link in our bio.
This year, we continue to protect what matters.